(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Viable Correspondence: Building Solid Connections - 2FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 3Audits of Thrillers That Re-imagined the Class
- 4The Most Well known Online Entertainment Forces to be reckoned with of 2023
- 5Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- The most effective method to Pick A Trade-in vehicle Stage
- Hubble sees spiral galaxy in Lion's heart | Space photo of the day for Nov. 4
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- The most effective method to Go with Informed Choices on Vehicle Leases
- Smartwatches: Remain Associated and Dynamic
- Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- Instructions to Pick the Best Album Rates for Your Investment funds
- Must-See Attractions in Washington, D.C.
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
